ClinicalTrials.gg
CompletedNCT00775463DISTOL-1Updated Dec 28, 2023Results posted

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

A Phase 2 interventional study of treprostinil diethanolamine and placebo in Systemic Sclerosis and Scleroderma, sponsored by United Therapeutics. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-28.

Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
27th of 142
148 · median 34
Started
2009
with 4 others
Phase 2
54 of 165
10 open now
Registered
33rd of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 27th largest by enrollment of the 142 interventional ones that give a count, is one of 5 that started in 2009, is one of 54 in phase 2, and was the 33rd registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.

03

Conditions studied

  • Systemic Sclerosis
  • Scleroderma

Keywords

  • Scleroderma, Diffuse
  • Scleroderma, Limited
  • Scleroderma, Systemic
  • Ulcer
  • prostacyclin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject gave voluntary written to participate in the study
  • Diagnosis of systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria
  • Males and females age greater than 18 years at Screening
  • Presence of at least one active digital ulcer (met protocol defined qualifications for active digital ulcer) at Baseline
  • Females of willing to use a reliable form of medically acceptable and have a negative pregnancy test at Screening and Baseline
  • Able to communicate effectively with study personnel and willing to comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of pulmonary arterial hypertension (PAH)
  • Body weight less than 40 kg at Screening and confirmed at Baseline
  • History of postural hypotension, unexplained syncope, a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic at Screening and Baseline
  • concentration less than 75% of the lower limit of the normal range at Screening
  • Moderate to severe hepatic impairment, i.e., Class B or C, or greater than three times
  • Intractable diarrhea, or severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening; any severe organ failure (e.g., lung, kidney), bleeding diathesis or disorder, or any life-threatening condition
  • Pregnant or breast-feeding
  • Simultaneously fulfilled criteria for a second connective tissue disease including systemic lupus erythermatosus, rheumatoid arthritis or inflammatory myopathy
  • Sympathectomy of the upper limb, involving the hand, performed within 12 months of Baseline. Sympathectomy performed on the non-target limb (hand not presenting with qualifying ulcers) or which did not include the hand, performed within 6 months of Baseline
  • Receipt of prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months of Baseline for conditions including Raynaud's phenomenon, rest pain and / or digital ulcers
  • Required systemic antibiotics for infected digital ulcers within 2 weeks of Screening
  • Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline
  • Treatment with endothelin receptor antagonists within 1 month prior to Baseline
  • Patients on phosphodiasterase inhibitors, such as sildenafil or tadalafil, who have received treatment for less than 6 months prior to Baseline (unless for intermittent treatment of male erectile dysfunction)
  • Treatment with statin within 1 month prior to Screening, unless for management of hyperlipidemia
  • Received an product within 1 month preceding Screening
  • Known to treprostinil diethanolamine or any of the
  • Tobacco or nicotine use at any level within the past 6 months prior to Screening
  • Any condition or laboratory that in the opinion of the investigator might interfere with subject's participation, pose an additional risk for the subject, could prevent understanding the objectives, nature or consequences of the trial, compliance with the protocol, adherence to therapy, or that would interfere with interpretation of study assessments
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    treprostinil diethanolamine

    Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.

    Drug: treprostinil diethanolamine

  • Placebo comparator
    placebo (sugar pill)

    Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Net Ulcer Burden

    Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.

    Time frame: Week 20

Secondary outcomes

  1. Digital Ulcer Pain VAS

    Digital ulcer pain was rated on a 100-mm VAS on which subjects were asked to rate their average overall hand pain during the last week. The recorded value was divided by 10, with values ranging from 0.0 (no pain) to 10.0 (unbearable pain), expressed to one decimal.

    Time frame: Week 20

  2. Patient Global Assessment of Digital Ulcer Severity VAS

    Patients rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.

    Time frame: Week 20

  3. Physician Global Assessment of Digital Ulcer Severity VAS

    Physicians rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.

    Time frame: Week 20

  4. Cochin Hand Function Scale (CHFS)

    The CHFS has been demonstrated as a reliable and valid assessment of hand function at the activity level in persons with SSc. It is comprised of 18 questions with possible integer responses of 0 (without difficulty) to 5 (impossible). The CHFS Score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS Score values can range from 0 (least limitation) to 90 (most limitation). A higher score indicates more difficulty in hand function or greater disability.

    Time frame: Week 20

  5. Scleroderma Health Assessment Questionnaire (SHAQ)

    The SHAQ is a patient self-administered instrument which has been previously validated in SSc and demonstrates meaningful clinical changes in the course of the disease over time. It is comprised of a 20 question instrument pertaining to specific activities with possible integer responses of 0 (without any difficulty) to 3 (unable to do), and five additional scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with possible values ranging from 0.0 to 15.0. The 20 questions are divided into eight domains. A mean score is calculated for each domain ranging from 0 to 3. A composite HAQ DI score is calculated by dividing the summed domain scores by the number of domains answered. The composite score is reported, falling between 0 and 3 on an ordinal scale. The scores are interpreted as 0 (no impairment in function) to 3 (maximal impairment of function).

    Time frame: Week 20

  6. Modified Rodnan Skin Score (mRSS)

    The skin thickening was assessed by the Investigator in 17 body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each area was scored 0-3; 0 representing normal skin and 3 being severe thickening. The mRSS was the sum of the individual skin assessment scores: possible range of 0-51; 0 (no thickening) to 51 (severe thickening in all 17 areas) .

    Time frame: Week 20

  7. Short-Form McGill Pain Questionnaire

    The SF-MPQ assessment has three component scores: the pain rating index (PRI), a pain visual analogue numerical scale (Pain VAS) and the present pain intensity (PPI). PRI is calculated by summing the responses (0=None to 3=Severe) to the 15 questions describing pain during the previous week and rated on an intensity scale as 0= none, 1= mild, 2= moderate or 3= severe and has possible values ranging from 0 to 45. The Pain VAS is a 100 mm VAS on which subjects were asked to rate pain during the previous week with values ranging from no pain (0.0) to worst possible pain (10.0). The PPI rated pain on a 6-point category scale from 0 (no pain) to 5 (excruciating pain).

    Time frame: Week 20

  8. Patient Impression of Change (PIC) Questionnaire

    The PIC questionnaire consisted of three Likert items that asked the subject to rate changes in their digital ulcer, Raynaud's phenomenon and disease status since their last visit on a seven-level scale (very much improved, much improved, somewhat improved, same, somewhat worse, much worse and very much worse).

    Time frame: Week 20

  9. Short Form 36

    Change in patient quality of life was measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a self-administered questionnaire covering eight areas: physical function, physical role, bodily pain, general health, vitality, social function, emotional role, and mental health. For each area, the score range from 0 (poorer health status) to 100 (better health status). The SF-36 is one of the most widely used and validated instruments to assess quality of life in patients with systemic illnesses. A decrease (negative change) in a domain score corresponds to deterioration.

    Time frame: Week 20

  10. Time to Ulcer Healing- Percentage of Subjects With Complete Healing

    A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial.

    Time frame: Week 20

  11. Time to Ulcer Healing

    A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial. The time to complete healing of all ulcers were calculated as the number of days from randomization to the date of these respective assessments, provided that complete healing was achieved during the study.

    Time frame: Week 20

07

Results

Posted Mar 17, 2014

Participant flow

Subjects were recruited across 32 clinical trial sites in the US, Canada and UK experienced in the treatment of systemic sclerosis (SSc) and capable of conducting the trial according to ICH GCP guidance. Subjects were recruited between April 2009 and October 2010.

Participant flow — Overall Study
MilestonePlaceboTreprostinil Diethanolamine
Started7672
Completed6559
Not completed1113
Withdrew: Withdrawal by subject01
Withdrew: Adverse event79
Withdrew: Protocol violation22
Withdrew: Lost to follow-up10
Withdrew: Lack of efficacy11

Outcome measures

PrimaryNet Ulcer Burden

Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.

Time frame:
Week 20
Reported as:
Median · ulcers
Net Ulcer Burden
ulcersPlaceboTreprostinil Diethanolamine
Baseline1.0 (1.0 to 2.0)2.0 (1.0 to 2.0)
Change at Week 200.0 (-1.0 to 1.0)-1.0 (-1.0 to 0.0)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Cochran-Mantel-Haenszel · p = 0.20 · Hodges-lehmann estimate of treatment eff: 0.0 · 95% CI -1.0 to 0.0
SecondaryDigital Ulcer Pain VAS

Digital ulcer pain was rated on a 100-mm VAS on which subjects were asked to rate their average overall hand pain during the last week. The recorded value was divided by 10, with values ranging from 0.0 (no pain) to 10.0 (unbearable pain), expressed to one decimal.

Time frame:
Week 20
Reported as:
Median · units on a scale
Digital Ulcer Pain VAS
units on a scalePlaceboTreprostinil Diethanolamine
Baseline4.85 (2.75 to 6.75)6.00 (2.80 to 7.70)
Change at Week 20-1.05 (-3.20 to 0.10)-1.45 (-4.60 to 0.00)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.31 (Analyses of secondary endpoints were descriptive in nature, no adjustments for multiplicity were made. P-values are for the purpose of describing the random imbalance between treatment groups and not to test formal hypotheses.) · Hodges-lehmann estimate of treatment eff: -0.40 · 95% CI -1.40 to 0.40
SecondaryPatient Global Assessment of Digital Ulcer Severity VAS

Patients rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.

Time frame:
Week 20
Reported as:
Median · units on a scale
Patient Global Assessment of Digital Ulcer Severity VAS
units on a scalePlaceboTreprostinil Diethanolamine
Baseline57.0 (29.3 to 79.7)67.0 (34.7 to 78.0)
Change at Week 20-24.0 (-43.0 to 0.0)-24.3 (-63.3 to -3.3)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.12 (Analyses of secondary endpoints were descriptive in nature, no adjustments for multiplicity were made. P-values are for the purpose of describing the random imbalance between treatment groups and not to test formal hypotheses.) · Hodges-lehmann estimate of treatment eff: -9.3 · 95% CI -21.3 to 2.7
SecondaryPhysician Global Assessment of Digital Ulcer Severity VAS

Physicians rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease). The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.

Time frame:
Week 20
Reported as:
Median · units on a scale
Physician Global Assessment of Digital Ulcer Severity VAS
units on a scalePlaceboTreprostinil Diethanolamine
Baseline44.7 (26.0 to 63.3)47.3 (31.3 to 66.7)
Change at Week 20-13.3 (-31.3 to -1.3)-26.7 (-43.3 to -5.3)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.04 (Analyses of secondary endpoints were descriptive in nature, no adjustments for multiplicity were made. P-values are for the purpose of describing the random imbalance between treatment groups and not to test formal hypotheses.) · Hodges-lehmann estimate of treatment eff: -9.3 · 95% CI -18.0 to 0.0
SecondaryCochin Hand Function Scale (CHFS)

The CHFS has been demonstrated as a reliable and valid assessment of hand function at the activity level in persons with SSc. It is comprised of 18 questions with possible integer responses of 0 (without difficulty) to 5 (impossible). The CHFS Score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS Score values can range from 0 (least limitation) to 90 (most limitation). A higher score indicates more difficulty in hand function or greater disability.

Time frame:
Week 20
Reported as:
Median · units on a scale
Cochin Hand Function Scale (CHFS)
units on a scalePlaceboTreprostinil Diethanolamine
Baseline18.5 (5.0 to 29.5)24.0 (11.0 to 37.0)
Week 2019.0 (4.0 to 33.5)21.0 (8.0 to 35.0)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.47 (Analyses of secondary endpoints were descriptive in nature, no adjustments for multiplicity were made. P-values are for the purpose of describing the random imbalance between treatment groups and not to test formal hypotheses.) · Hodges-lehmann estimate of treatment eff: -1.0 · 95% CI -4.0 to 2.0
SecondaryScleroderma Health Assessment Questionnaire (SHAQ)

The SHAQ is a patient self-administered instrument which has been previously validated in SSc and demonstrates meaningful clinical changes in the course of the disease over time. It is comprised of a 20 question instrument pertaining to specific activities with possible integer responses of 0 (without any difficulty) to 3 (unable to do), and five additional scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with possible values ranging from 0.0 to 15.0. The 20 questions are divided into eight domains. A mean score is calculated for each domain ranging from 0 to 3. A composite HAQ DI score is calculated by dividing the summed domain scores by the number of domains answered. The composite score is reported, falling between 0 and 3 on an ordinal scale. The scores are interpreted as 0 (no impairment in function) to 3 (maximal impairment of function).

Time frame:
Week 20
Reported as:
Median · units on a scale
Scleroderma Health Assessment Questionnaire (SHAQ)
units on a scalePlaceboTreprostinil Diethanolamine
Dressing & Grooming Score: Baseline (76/71)0.50 (0.00 to 1.00)1.00 (0.50 to 1.50)
Dressing&Grooming Score:Change at Week 200.00 (0.00 to 0.00)0.00 (-0.50 to 0.00)
Arising Score: Baseline (76/71)0.00 (0.00 to 1.00)0.00 (0.00 to 1.00)
Arising Score: Change at Week 200.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Eating Score: Baseline (76/71)0.67 (0.00 to 1.00)0.67 (0.33 to 1.00)
Eating Score: Change at Week 200.00 (-1.17 to 0.08)0.00 (-0.33 to 0.17)
Walking Score: Baseline (76/71)0.00 (0.00 to 0.50)0.00 (0.00 to 0.50)
Walking Score: Change at Week 200.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Hygiene Score: Baseline (76/68)0.00 (0.00 to 0.67)0.33 (0.00 to 0.67)
Hygiene Score: Change at Week 200.00 (0.00 to 0.33)0.00 (0.00 to 0.33)
Reach Score: Baseline (76/68)0.00 (0.00 to 1.00)0.50 (0.00 to 1.00)
Reach Score: Change at Week 200.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Grip Score: Baseline (76/68)0.33 (0.00 to 0.67)0.33 (0.17 to 1.00)
Grip Score: Change at Week 200.00 (0.00 to 0.33)0.00 (-0.33 to 0.00)
Activity Score: Baseline (76/68)0.33 (0.00 to 1.00)0.67 (0.00 to 1.00)
Activity Score: Change at Week 200.00 (0.00 to 0.33)0.00 (0.00 to 0.17)
HAQ Aggregate Score: Baseline (76/68)0.34 (0.10 to 0.77)0.53 (0.26 to 0.81)
HAQ Aggregate Score: Change at Week 200.00 (-0.07 to 0.13)-0.03 (-0.16 to 0.12)
Hand Function Aggregate Score: Baseline (76/68)0.39 (0.11 to 0.69)0.56 (0.28 to 0.86)
Hand Function Aggregate Score: Change at Week 200.00 (-0.06 to 0.17)0.00 (-0.22 to 0.11)
Raynaud's Phenomenon VAS Score: Baseline (75/71)0.12 (0.00 to 0.64)0.18 (0.02 to 0.80)
Raynaud's Phenomenon VAS Score: Change at Week 200.00 (-0.14 to 0.08)0.00 (-0.14 to 0.14)
Intestinal Problems VAS Score: Baseline (75/70)0.20 (0.00 to 0.70)0.11 (0.02 to 0.62)
Intestinal Problems VAS Score: Change at Week 200.00 (-0.10 to 0.24)0.11 (-0.02 to 0.72)
Digital Ulcer VAS Score: Baseline (76/71)1.43 (0.49 to 2.09)1.50 (0.68 to 2.28)
Digital Ulcer VAS Score: Change at Week 20-0.34 (-0.92 to 0.00)-0.56 (-1.36 to 0.00)
Breathing Problems VAS Score: Baseline (76/71)1.54 (0.95 to 2.31)2.16 (0.96 to 2.54)
Breathing Problems VAS Score: Change at Week 20-0.50 (-1.15 to 0.00)-0.84 (-2.14 to -0.20)
Pain VAS Score: Baseline (76/69)1.27 (0.57 to 1.91)1.54 (0.54 to 2.16)
Pain VAS Score: Change at Week 20-0.26 (-0.93 to 0.11)-0.34 (-1.44 to 0.00)
Overall Disease VAS Score: Baseline (76/71)1.22 (0.67 to 1.87)1.52 (0.74 to 2.12)
Overall Disease VAS Score: Change at Week 20-0.18 (-0.60 to 0.04)-0.32 (-1.00 to 0.10)
SecondaryModified Rodnan Skin Score (mRSS)

The skin thickening was assessed by the Investigator in 17 body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each area was scored 0-3; 0 representing normal skin and 3 being severe thickening. The mRSS was the sum of the individual skin assessment scores: possible range of 0-51; 0 (no thickening) to 51 (severe thickening in all 17 areas) .

Time frame:
Week 20
Reported as:
Median · units on a scale
Modified Rodnan Skin Score (mRSS)
units on a scalePlaceboTreprostinil Diethanolamine
Baseline6.0 (3.0 to 12.0)8.0 (5.0 to 14.0)
Week 206.0 (3.0 to 12.0)6.0 (3.0 to 15.0)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.68 · Hodges-lehmann estimate of treatment eff: 0.0 · 95% CI 0.0 to 1.0
SecondaryShort-Form McGill Pain Questionnaire

The SF-MPQ assessment has three component scores: the pain rating index (PRI), a pain visual analogue numerical scale (Pain VAS) and the present pain intensity (PPI). PRI is calculated by summing the responses (0=None to 3=Severe) to the 15 questions describing pain during the previous week and rated on an intensity scale as 0= none, 1= mild, 2= moderate or 3= severe and has possible values ranging from 0 to 45. The Pain VAS is a 100 mm VAS on which subjects were asked to rate pain during the previous week with values ranging from no pain (0.0) to worst possible pain (10.0). The PPI rated pain on a 6-point category scale from 0 (no pain) to 5 (excruciating pain).

Time frame:
Week 20
Reported as:
Median · units on a scale
Short-Form McGill Pain Questionnaire
units on a scalePlaceboTreprostinil Diethanolamine
Total Pain Rating Index Score Change at Week 20-4.0 (-8.0 to 1.0)-3.0 (-12.0 to 0.0)
Pain VAS Score Change at Week 20-0.6 (-2.9 to 0.3)-1.1 (-4.4 to 0.2)
Present Pain Intensity Score Change at Week 200.0 (-1.0 to 0.0)-1.0 (-1.0 to 0.0)
Statistical analysis
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.54 (P value for Total Pain Rating Index Score) · Hodges-lehmann estimate of treatment eff: -1.0 · 95% CI -3.0 to 2.0
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.18 (P value for Pain VAS) · Hodges-lehmann estimate of treatment ef: -0.6 · 95% CI -1.6 to 0.3
  • Placebo vs Treprostinil Diethanolamine · Wilcoxon (Mann-Whitney) · p = 0.10 (P value for Total Pain Rating Index Score) · Hodges-lehmann estimate of treatment eff: 0.0 · 95% CI -1.0 to 0.0
SecondaryPatient Impression of Change (PIC) Questionnaire

The PIC questionnaire consisted of three Likert items that asked the subject to rate changes in their digital ulcer, Raynaud's phenomenon and disease status since their last visit on a seven-level scale (very much improved, much improved, somewhat improved, same, somewhat worse, much worse and very much worse).

Time frame:
Week 20
Reported as:
Number · participants
Patient Impression of Change (PIC) Questionnaire
participantsPlacebo- Digital Ulcer ResponseTreprostinil Diethanolamine- Digital Ulcer ResponsePlacebo- Raynaud's Phenomenon ResponseTreprostinil Diethanolamine- Raynaud's Phenomenon ResponsePlacebo- Overall Disease Status ResponseTreprostinil Diethanolamine- Overall Disease Status Response
Very Much Improved590303
Much Improved1115412517
Somewhat Improved201412202213
Same242140303027
Somewhat Worse1481741810
Much Worse131100
Very Much Worse112111
SecondaryShort Form 36

Change in patient quality of life was measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a self-administered questionnaire covering eight areas: physical function, physical role, bodily pain, general health, vitality, social function, emotional role, and mental health. For each area, the score range from 0 (poorer health status) to 100 (better health status). The SF-36 is one of the most widely used and validated instruments to assess quality of life in patients with systemic illnesses. A decrease (negative change) in a domain score corresponds to deterioration.

Time frame:
Week 20
Reported as:
Median · units on a scale
Short Form 36
units on a scalePlaceboTreprostinil Diethanolamine
Physical Component: Baseline55.0 (39.5 to 67.5)50.7 (35.1 to 62.9)
Physical Component: Change at Week 202.8 (-5.3 to 10.9)3.8 (-2.1 to 10.3)
Physical Functioning: Baseline62.5 (30.0 to 80.0)60.0 (35.0 to 75.0)
Physical Functioning: Change at Week 200.0 (-5.0 to 10.0)0.0 (-10.0 to 10.0)
Role-Physical: Baseline54.4 (37.5 to 72.5)50.0 (25.0 to 70.0)
Role-Physical: Change at Week 200.0 (-10.0 to 17.5)0.0 (0.0 to 22.5)
Bodily Pain: Baseline57.5 (33.8 to 67.5)45.0 (32.5 to 75.0)
Bodily Pain: Change at Week 2010.0 (-5.0 to 21.3)10.0 (-2.5 to 22.5)
General Health: Baseline42.0 (34.0 to 65.0)45.0 (30.0 to 63.0)
General Health: Change at Week 200.0 (-9.5 to 5.0)0.0 (-5.0 to 6.0)
Mental Component: Baseline68.3 (54.1 to 77.4)64.2 (49.2 to 76.1)
Mental Component: Change at Week 202.6 (-8.6 to 11.0)4.0 (-4.0 to 15.7)
Vitality: Baseline (75/71)50.0 (31.3 to 62.5)43.8 (25.0 to 61.3)
Vitality: Change at Week 200.0 (-6.3 to 7.5)1.3 (-6.3 to 17.5)
Social Functioning: Baseline72.5 (50.0 to 87.5)62.5 (50.0 to 85.0)
Social Functioning: Change at Week 200.0 (-12.5 to 13.8)10.0 (0.0 to 22.5)
Role-Emotional: Baseline70.0 (60.8 to 95.0)80.0 (50.0 to 100.0)
Role-Emotional: Change at Week 200.0 (-5.8 to 11.7)0.0 (-1.7 to 13.3)
Mental Health: Baseline (75/71)69.0 (52.0 to 84.0)64.0 (54.0 to 79.0)
Mental Health: Change at Week 202.0 (-6.0 to 11.0)3.0 (-5.0 to 16.0)
SecondaryTime to Ulcer Healing- Percentage of Subjects With Complete Healing

A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial.

Time frame:
Week 20
Reported as:
Number · percentage of participants
Time to Ulcer Healing- Percentage of Subjects With Complete Healing
percentage of participantsPlaceboTreprostinil Diethanolamine
Cardinal Ulcer Healed6162
All Ulcers Healed4149
SecondaryTime to Ulcer Healing

A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial. The time to complete healing of all ulcers were calculated as the number of days from randomization to the date of these respective assessments, provided that complete healing was achieved during the study.

Time frame:
Week 20
Reported as:
Mean · days
Time to Ulcer Healing
daysPlaceboTreprostinil Diethanolamine
Time to Cardinal Ulcer Healing83.2 ± 37.976.3 ± 35
Time to All Ulcers Healed96.7 ± 39.790.2 ± 35.6

Adverse events

Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/76 (0%)4/76 (5.3%)74/76 (97.4%)
Treprostinil Diethanolamine0/71 (0%)9/71 (12.7%)71/71 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPlaceboTreprostinil Diethanolamine
PneumothoraxRespiratory, thoracic and mediastinal disorders0/762/71
PneumoniaInfections and infestations1/761/71
GastroenteritisInfections and infestations0/761/71
DyspnoeaRespiratory, thoracic and mediastinal disorders0/761/71
HypoxiaRespiratory, thoracic and mediastinal disorders0/761/71
VomitingGastrointestinal disorders1/761/71
ConstipationGastrointestinal disorders0/761/71
Erosive oesophagitisGastrointestinal disorders0/761/71
Gastric ulcer haemorrhageGastrointestinal disorders0/761/71
Gastrointestinal haemorrhageGastrointestinal disorders0/761/71
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPlaceboTreprostinil Diethanolamine
HeadacheNervous system disorders32/7652/71
NauseaGastrointestinal disorders14/7642/71
DiarrhoeaGastrointestinal disorders16/7640/71
Pain in jawMusculoskeletal and connective tissue disorders4/7617/71
FlushingVascular disorders3/7617/71
FatigueGeneral disorders15/7616/71
Infected skin ulcerSkin and subcutaneous tissue disorders10/7613/71
Pain in extremityMusculoskeletal and connective tissue disorders12/7612/71
VomitingGastrointestinal disorders4/7612/71
PainGeneral disorders1/7612/71

Baseline characteristics

Baseline demographics and characteristics were summarized for subjects who received at least one dose of study drug. One subject in the treprostinil diethanolamine treatment group was randomized, withdrew consent and exited the study prior to taking any study medication and is not included in the summary.

Age, Continuous
Age, Continuous(years)PlaceboTreprostinil DiethanolamineTotal
Mean47.8 (20 to 74)49.8 (19 to 82)48.8 (19 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTreprostinil DiethanolamineTotal
Female5554109
Male211738
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboTreprostinil DiethanolamineTotal
Asian347
Native Hawaiian or Other Pacific Islander011
Black or African American10717
White6259121
Unknown or Not Reported112
SSc Classification
SSc Classification(participants)PlaceboTreprostinil DiethanolamineTotal
Limited554095
Diffuse213152
Years since SSc diagnosis
Years since SSc diagnosis(years)PlaceboTreprostinil DiethanolamineTotal
Mean10.7 (0 to 30)10.3 (0 to 35)10.5 (0 to 35)
08

Study locations

30 sites
  • University of Alabama - Arthritis Clinical Intervention Program
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Stanford University School of Medicine/Palo Alto VA Health Care System
    Palo Alto, California 94304, United States
  • Denver Medical Center
    Aurora, Colorado 80045, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06030, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Northwestern University - Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Indiana School of Medicine
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins University - Division of Rheumatology
    Baltimore, Maryland 21224, United States
  • Boston University School of Medicine
    Boston, Massachusetts 02118, United States
  • University of Michigan Scleroderma Program
    Ann Arbor, Michigan 48106, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • UMDNJ Clinical Research Center
    New Brunswick, New Jersey 08903, United States
  • North Shore-LIJ Health System
    Lake Success, New York 11042, United States
  • The Hospital for Special Surgery
    New York, New York 10021, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Toledo
    Toledo, Ohio 43614, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas - Houston
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98111, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Dalhousie University - QEII Health Science Center
    Halifax, Nova Scotia B3H4K4, Canada
  • St Joseph's Health Care
    London, Ontario N6A4V2, Canada
  • McGill University
    Montreal, Quebec H3T1E2, Canada
  • Clinical Sciences Center - University Hospital
    Liverpool, L9 7AL, United Kingdom
  • Royal Free Hospital - Center for Rheumatology
    London, NW32QG, United Kingdom
  • Salford Royal Hospital
    Manchester, M139PT, United Kingdom
09

References and documents

Publications

  • Mecoli CA, Perin J, Van Eyk JE, Zhu J, Fu Q, Allmon AG, Rao Y, Zeger S, Wigley FM, Hummers LK, Shah AA. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). Clin Rheumatol. 2020 Apr;39(4):1199-1205. doi: 10.1007/s10067-019-04863-0. Epub 2019 Dec 19. PubMed 31858338 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Mar 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years after primary completion. A results delay was requested in Feb 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2008
First posted
Oct 20, 2008
Start
May 2009
Primary completionActual
Mar 2011
CompletionActual
Jul 2011
Results delay requested
Feb 26, 2013
Results first posted
Mar 17, 2014
Last update
Dec 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00775463
Responsible party
Sponsor
First posted
Oct 20, 2008
Start date
May 2009
Primary completion
Mar 2011
Completion
Jul 2011
Results posted
Mar 17, 2014
Last update
Dec 28, 2023

Study contacts

James Seibold, MD
principal investigator · Scleroderma Research Consultants LLC, Avon, CT,

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion